Skip to main content

Advertisement

SpringerLink
Log in

Intravitreal anti‑VEGF agents and cardiovascular risk: comment

  • CE - LETTER TO THE EDITOR
  • Published:
Internal and Emergency Medicine Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

References

  1. Port M, Striglia E (2020) Intravitreal anti-VEGF agents and cardiovascular risk. Intern Emerg Med 15:199–210

    Article  Google Scholar 

  2. Berger V, Munk MR, Lersch F, Wolf S, Ebneter A, Zinkernagel MS (2019) Association of intravitreal injections with blood pressure increase: the following excitement and anxiety response under intravitreal injection study. JAMA Ophth 137(1):87–90

    Article  Google Scholar 

  3. Oakley CL, Allen PL, Vote BJ (2016) Effect of intravitreal anti-vascular endothelial growth factor agents on blood pressure–a cross-sectional analysis. J Hyperten 34(10):2099–2100

    Article  CAS  Google Scholar 

  4. Rasier R, Artunay O, Yuzbasioglu E, Sengul A, Bahcecioglu H (2009) The effect of intravitreal bevacizumab (avastin) administration on systemic hypertension. Eye 23(8):1714

    Article  CAS  Google Scholar 

  5. Sengul A, Rasier R, Ciftci C, Artunay O, Kockar A, Bahcecioglu H et al (2017) Short-term effects of intravitreal ranibizumab and bevacizumab administration on 24-h ambulatory blood pressure monitoring recordings in normotensive patients with age-related macular degeneration. Eye 31(5):677

    Article  CAS  Google Scholar 

  6. Lee K, Yang H, Lim H, Lew HM (2009) A prospective study of blood pressure and intraocular pressure changes in hypertensive and nonhypertensive patients after intravitreal bevacizumab injection. Retina 29(10):1409–1417

    Article  Google Scholar 

Download references

Acknowledgements

The authors wish to thank the Practice Manager, Jennie Rossetto for supporting the study and the technical staff of the Tasmanian Eye Institute for assisting in collecting blood pressure measurements.

Author information

Authors and Affiliations

  1. Tasmanian Eye Institute, 36 Thistle Street West, Launceston, TAS, 7250, Australia

    Philip S. Rothschild, Penelope L. Allen, Joobin Hooshmand & Brendan J. Vote

  2. Launceston Clinical School, College of Health and Medicine, University of Tasmania, Launceston General Hospital, Launceston, TAS, Australia

    Philip S. Rothschild & Brendan J. Vote

  3. Rural Clinical School, College of Health and Medicine, University of Tasmania, Hospitals’ Campus, Brickport Road, Burnie, TAS, Australia

    Penelope L. Allen

Authors
  1. Philip S. Rothschild
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Penelope L. Allen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joobin Hooshmand
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Brendan J. Vote
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Penelope L. Allen.

Ethics declarations

Conflicts of interest

The authors do not have any relevant conflicts of interest to declare.

Ethical approval

Ethical approval for the study was obtained from the University of Tasmania Human Research Ethics Committee.

Informed consent

All participants provided informed consent prior to their participation.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rothschild, P.S., Allen, P.L., Hooshmand, J. et al. Intravitreal anti‑VEGF agents and cardiovascular risk: comment. Intern Emerg Med 16, 533–536 (2021). https://doi.org/10.1007/s11739-020-02455-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11739-020-02455-4

Search

Navigation